Boston Scientific reports positive study data at ACC 2014

Boston Scientific has shared positive clinical findings on a number of its technological innovations at last week's annual scientific session of the American College of Cardiology.

During the event in Washington DC, the company reported data from a long-term study showing the significant and sustained survival benefit associated with its cardiac resynchronisation therapy devices, which offer longer-lasting batteries than any other products.

Dr Kenneth Stein, chief medical officer for rhythm management at Boston Scientific, said its technology "can minimise the requirement for additional device implants, reducing risks to patients and thus reducing costs for the global healthcare system".

The meeting also saw Boston Scientific release new data showing how its Platinum chromium coronary stent platform demonstrates low event rates over four years, while another presentation underlined the impressive performance of its transcatheter aortic valve replacement technology after three months.

Earlier this week, the company also reported positive real-world data from a study of S-ICD, its subcutaneous implantable defibrillator.